Skip to main content
. 2023 Aug 18;13(1):126. doi: 10.1038/s41408-023-00900-z

Table 2.

Univariate analysis of OS and PFS by patient, treatment, and disease characteristics.

N 5-yr OS % OS HR (95% CI, p = ) 5-yr PFS % PFS HR (95% CI, p = )
Entire Cohort 85 22.2 N/A 15.1
Age
  <50 38 27.9 Ref. 15.8 Ref.
  50+ 47 18.0 1.36 (0.37–2.21, p = 0.22) 12.1 1.33 (0.84–2.12, p = 0.23)
Sex
  Male 61 22.6 Ref. 16.1 Ref.
  Female 24 20.8 1.26 (0.75–2.11, p = 0.38) 12.5 1.27 (0.77–2.11, p = 0.34)
Race
  White 76 22.1 16.9
  Unknown 4 0 0
   Other 3 0 0
  Black or African American 1 0 0
  Asian Chinese 1 100 0
Prior Auto SCT(s)
  0 4 50.0 Ref. 0.75 Ref.
  1 63 24.4 2.62 (0.63–10.83, p = 0.18) 0.14 2.49 (0.76–8.16, p = 0.13)
  2 18 0 5.68 (1.28–25.22, p = 0.02*) 0 4.86 (1.36–17.39, p = 0.02*)
Years MM Dx to Allo SCT
  0–2 20 30.0 Ref. 18.7 Ref.
   2–5 48 19.8 1.24 (0.68–2.23, p = 0.47) 12.9 1.39 (0.78–2.48, p = 0.27)
  5+ 17 18.1 1.28 (0.61–2.66, p = 0.51) 9.6 1.44 (0.71–2.93, p = 0.31)
Years Auto SCT1 to Allo SCT (N = 81)
  0–2 years 45 20.0 Ref. 10.5 Ref.
   2+ years 36 18.4 1.11 (0.68–1.82, p = 0.67) 10.8 1.15 (0.72–1.84, p = 0.57)
Auto SCT1 Response at Day 100 (N = 70)
  CR 30 29.2 Ref. 19.1 Ref.
  VGPR 10 30.0 0.93 (0.39–2.18, p = 0.86) 20.0 0.79 (0.35–1.75, p = 0.55)
  PR 25 12.0 1.96 (1.08–3.56, p = 0.03*) 8.5 1.30 (0.73–2.31, p = 0.36)
  Progression 5 20.0 1.40 (0.39–2.18, p = 0.86) 0 1.31 (0.50–3.45, p = 0.58)
Years Auto SCT2 to Allo SCT (N = 18)
  0–2 years 14 0 Ref. 0 Ref.
  2+ years 4 25 0.64 (0.18–2.27, p = 0.49) 25 0.40 (0.11–1.44, p = 0.16)
Auto SCT2 Response at Day 100 (N = 10)
  CR 1 0 Ref. 100
  VGPR 1 0 0.71 (0.04–12.31, p = 0.82) 0
  PR 6 33.3 0.33 (0.03–3.52, p = 0.36) 0
  Progression 2 0 0.49 (0.03–7.10, p = 0.60) 0
Allo Date
   2000–2010 46 23.9 Ref. 14.6 Ref.
  2011- 39 20.3 1.32 (0.82–2.15, p = 0.26) 16.0 1.27 (0.79–2.02, p = 0.32)
Response Status Going Into Allo SCT (N = 78)
  CR 14 42.9 Ref. 35.9 Ref.
  VGPR 11 11.3 1.94 (0.74–5.07, p = 0.18) 9.1 2.41 (0.93–6.23, p = 0.06)
   PR 22 21.2 1.81 (0.81–4.02, p = 0.15) 5.9 2.13 (0.93–4.88, p = 0.07)
  Stable disease 7 28.6 1.35 (0.45–4.04, p = 0.59) 28.6 1.58 (0.54–4.62, p = 0.40)
  Progression 24 10.4 3.39 (1.54–7.46, p = <0.01*) 4.2 4.39 (1.93–9.98, p = <0.01*)
Cytogenetic Risk (N = 80)
  Standard 53 22.1 Ref. 16.9 Ref.
   High risk* 27 11.5 1.10 (0.66–1.82, p = 0.72) 10.2 1.35 (0.79–2.28, p = 0.26)
Transplant Intensity
  MA 47 28.3 Ref. 19.8 Ref.
  RIC 26 20.1 0.93 (0.54–1.60, p = 0.79) 13.8 0.85 (0.50–1.45, p = 0.56)
  NMA 12 8.3 1.18 (0.60–2.30, p = 0.63) 0 1.22 (0.63–2.37, p = 0.55)
Transplant course:
  Standalone MA allo SCT 47 28.3 Ref. 19.8 Ref.
  Standalone RIC allo SCT 15 14.4 1.20 (0.63–2.27, p = 0.59) 7.2 1.04 (0.56–1.96, p = 0.90)
  Standalone NMA allo SCT 6 0 1.22 (0.50–2.93, p = 0.66) 0 1.36 (0.57–3.23, p = 0.49)
  Upfront auto SCT to RIC allo SCT 3 33.3 0.78 (0.24–2.55, p = 0.68) 0 0.86 (0.23–2.80, p = 0.80)
  Auto SCT to RIC (or NMA) allo SCT for relapse 14 21.4 0.84 (0.42–1.65, p = 0.60) 19.1 0.78 (0.40–1.53, p = 0.47)
Acute GVHD
  Present 50 23.6 Ref. 11.7 Ref.
  Absent 35 18.9 0.91 (0.56–1.49, p = 0.71) 19.9 0.93 (0.58–1.49, p = 0.75)
Chronic GVHD
  Present 38 23.1 Ref. 16.2 Ref.
  Absent 47 18.0 1.65 (1.02–2.71, p = 0.04) 14.2 1.34 (0.84–2.13, p = 0.22)
Lines of Therapy Before Allo SCT
  1–3 21 23.8 Ref. 12.9 Ref.
  4–6 48 25.7 1.03 (0.57–1.81, p = 0.91) 19.3 1.05 (0.59–1.85, p = 0.87)
  7+ 16 0 1.50 (0.71–3.16, p = 0.28) 0 1.97 (0.98–3.97, p = 0.06)
Donor Type (N = 84)
 PBSC Related 50 21.0 Ref. 16.3 Ref.
 PBSC Unrelated 32 22.3 0.89 (0.54–1.49, p = 0.67) 14.9 0.94 (0.58–1.53, p = 0.82)
 Single UC Unrelated 1 0 1.01 (0.14–7.41, p = 0.99) 0 1.02 (0.14–7.57, p = 0.97)
 Double UC Unrelated 1 0 9.6 (1.19–77.46, p = 0.04*) 0 8.61 (1.08–68.50, p = 0.04*)

HR Hazard Ratio.

Ref. Reference variable for hazard ratio generation.

Auto SCT autologous stem cell transplant.

Allo SCT allogeneic stem cell transplant.

CR complete response.

VGPR very good partial response.

PR partial response.

MA myeloablative.

RIC reduced-intensity chemotherapy.

NMA nonmyeloablative.

GVHD graft-versus host disease.

PBSC peripheral blood stem cell.

UC umbilical cord.

*p < 0.05.

Bold entries denote statistically significant p values.